Trial reportAnnals of the American Thoracic Society2015
Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.
Trial report in Annals of the American Thoracic Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- The role of ultrasound of the quadriceps femoris in people with cystic fibrosis: a systematic review and meta-analysis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2026Pooled it
- C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Trial
- Vitamin D treatment modulates immune activation in cystic fibrosis.Clinical and experimental immunology · 2017Trial
- Symptom phenotyping in people with cystic fibrosis during acute pulmonary exacerbations using machine-learning K-means clustering analysis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024Article
- Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis.International journal of molecular sciences · 2024Article
- Predicting return of lung function after a pulmonary exacerbation using the cystic fibrosis respiratory symptom diary-chronic respiratory infection symptom scale.BMC pulmonary medicine · 2024Observational
- Article
- Integrating airway microbiome and blood proteomics data to identify multi-omic networks associated with response to pulmonary infection.The microbe · 2023Article
- Diagnosis and Management of Cystic Fibrosis Exacerbations.Seminars in respiratory and critical care medicine · 2023Review
- Article
- Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging.Frontiers in pediatrics · 2022Review
- A pilot study of cystic fibrosis exacerbation response phenotypes reveals contrasting serum and sputum iron trends.Scientific reports · 2021Observational
- Calprotectin in Lung Diseases.International journal of molecular sciences · 2021Review
- Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2020Article
- CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis.Frontiers in pharmacology · 2020Article
- Acute Pulmonary Exacerbations in Cystic Fibrosis.Seminars in respiratory and critical care medicine · 2019Review
- Identification of novel blood biomarkers of treatment response in cystic fibrosis pulmonary exacerbations by label-free quantitative proteomics.Scientific reports · 2019Article
- G-CSF and GM-CSF Modify Neutrophil Functions at Concentrations found in Cystic Fibrosis.Scientific reports · 2019Article
- Poor recovery from a pulmonary exacerbation does not lead to accelerated FEVJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2017Article
- Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
Abstract
rationaleIn cystic fibrosis (CF), pulmonary exacerbations present an opportunity to define the effect of antibiotic therapy on systemic measures of inflammation.
objectivesInvestigate whether plasma inflammatory proteins demonstrate and predict a clinical response to antibiotic therapy and determine which proteins are associated with measures of clinical improvement.
methodsIn this multicenter study, a panel of 15 plasma proteins was measured at the onset and end of treatment for pulmonary exacerbation and at a clinically stable visit in patients with CF who were 10 years of age or older. MEASUREMENTS AND MAIN
resultsSignificant reductions in 10 plasma proteins were observed in 103 patients who had paired blood collections during antibiotic treatment for pulmonary exacerbations. Plasma C-reactive protein, serum amyloid A, calprotectin, and neutrophil elastase antiprotease complexes correlated most strongly with clinical measures at exacerbation onset. Reductions in C-reactive protein, serum amyloid A, IL-1ra, and haptoglobin were most associated with improvements in lung function with antibiotic therapy. Having higher IL-6, IL-8, and α1-antitrypsin (α1AT) levels at exacerbation onset were associated with an increased risk of being a nonresponder (i.e., failing to recover to baseline FEV1). Baseline IL-8, neutrophil elastase antiprotease complexes, and α1AT along with changes in several plasma proteins with antibiotic treatment, in combination with FEV1 at exacerbation onset, were predictive of being a treatment responder.
conclusionsCirculating inflammatory proteins demonstrate and predict a response to treatment of CF pulmonary exacerbations. A systemic biomarker panel could speed up drug discovery, leading to a quicker, more efficient drug development process for the CF community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.